Dirk M van der Steen Selected Research

Neoplasms (Cancer)

3/2023	A library of cancer testis specific T cell receptors for T cell receptor gene therapy.
1/2023	PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer.
1/2022	Cutting Edge: Unconventional CD8+ T Cell Recognition of a Naturally Occurring HLA-A*02:01-Restricted 20mer Epitope.
1/2022	WT1-specific TCRs directed against newly identified peptides install antitumor reactivity against acute myeloid leukemia and ovarian carcinoma.
1/2022	A broad and systematic approach to identify B cell malignancy-targeting TCRs for multi-antigen-based T cell therapy.
1/2021	Healthy cells functionally present TAP-independent SSR1 peptides: implications for selection of clinically relevant antigens.
1/2018	PRAME and HLA Class I expression patterns make synovial sarcoma a suitable target for PRAME specific T-cell receptor gene therapy.
1/2017	PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.
1/2017	TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor BOB1.
11/2016	Generation of CD20-specific TCRs for TCR gene therapy of CD20low B-cell malignancies insusceptible to CD20-targeting antibodies.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Dirk M van der Steen Research Topics

Disease

13	Neoplasms (Cancer) 03/2023 - 09/2011
3	Melanoma (Melanoma, Malignant) 03/2023 - 09/2011
2	Multiple Myeloma 01/2023 - 01/2017
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2022 - 01/2019
2	Testicular Neoplasms (Testicular Cancer) 01/2018 - 01/2017
2	Graft vs Host Disease (Graft-Versus-Host Disease) 12/2011 - 09/2011
1	Ovarian Neoplasms (Ovarian Cancer) 01/2023
1	Carcinoma (Carcinomatosis) 01/2022
1	Leukemia 01/2022
1	Sarcoma (Soft Tissue Sarcoma) 01/2018
1	Synovial Sarcoma (Synovioma) 01/2018
1	Hematologic Neoplasms (Hematological Malignancy) 01/2017
1	Neoplasm Metastasis (Metastasis) 01/2017
1	Uveal melanoma 01/2017
1	Lymphoma (Lymphomas) 11/2016
1	B-Cell Leukemia (Leukemia, B Cell) 11/2016
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 11/2016
1	Neuroblastoma 11/2015
1	Adenoviridae Infections (Adenovirus Infections) 11/2010
1	Viremia 11/2010

Drug/Important Bio-Agent (IBA)

10	AntigensIBA 03/2023 - 09/2011
8	Peptides (Polypeptides)IBA 03/2023 - 09/2011
4	Monoclonal AntibodiesIBA 01/2017 - 02/2015
3	HLA Antigens (Human Leukocyte Antigens)IBA 03/2023 - 09/2011
3	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2023 - 01/2017
3	Messenger RNA (mRNA)IBA 01/2023 - 01/2017
3	Chimeric Antigen ReceptorsIBA 01/2017 - 02/2015
2	CytokinesIBA 01/2022 - 11/2016
2	Transcription Factors (Transcription Factor)IBA 01/2022 - 01/2017
2	HLA-B*07 antigenIBA 11/2016 - 11/2016
1	Immunoglobulins (Immunoglobulin)IBA 01/2023
1	HLA-A Antigens (HLA-A)IBA 01/2023
1	T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA 01/2022
1	transporter associated with antigen processing (TAP)IBA 01/2021
1	AutoantigensIBA 01/2021
1	NucleophosminIBA 01/2019
1	AntibodiesIBA 11/2016
1	Oncogene Proteins (Oncogene Protein)IBA 11/2015
1	Histocompatibility Antigens Class IIBA 11/2015
1	EpitopesIBA 11/2010

Therapy/Procedure

9	Therapeutics 03/2023 - 11/2015
6	Immunotherapy 01/2019 - 02/2015
2	Stem Cell Transplantation 09/2011 - 11/2010
1	Traction 11/2015